|
 |
Chief Executive Officer |
|
| |
| Dr. Rosenberg is responsible for providing vision, leadership and direction to IPM. Previously, Dr. Rosenberg was the scientific director for the HIV Prevention Trials Network at Family Health International from 1999 to 2002. In that role, she assured scientific and operational coordination for domestic and international clinical trials designed to prevent HIV transmission from mother to child and through sexual contact and through injection drug use. From 1987 to 1999, Dr. Rosenberg worked in several capacities at the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health. In her role as senior scientist at NIAID’s Division of AIDS, she was responsible for HIV-prevention clinical trials in adult populations. As assistant director for prevention research, she coordinated prevention activities for HIV and other sexually transmitted infections as well as tuberculosis, represented NIH on the Public Health Service Task Force to Combat Multi-Drug Resistant TB and co-chaired the TB Research Subcommittee. Dr. Rosenberg received her undergraduate degree in biology and mathematics from Douglass College, Rutgers University; a master’s degree (S.M.) in epidemiology and a doctoral degree (ScD) in microbiology from the Harvard School of Public Health. |
| |
|
|
 |
Chief Medical Officer |
|
| |
| Dr. Nel is responsible for IPM’s clinical trials and international clinical site development. Previously, Dr. Nel worked as an independent clinical research consultant in the drug development process. She has significant experience in all levels of clinical research and in a broad range of therapeutic areas, and she has worked as an investigator in clinical research for more than 20 years. Before serving as a consultant, Dr. Nel worked for Quintiles in South Africa, and was the founding staff member of its Cape Town office, responsible for the general management of the office and clinical operations. In 2004, Dr. Nel became head of business development for Quintiles, Africa. Prior to joining Quintiles, she worked as a medical officer in numerous therapeutic areas and lectured in pharmacology, pulmonology and toxicology at the Tygerberg campus of the University of Stellenbosch Medical School. Dr. Nel also has been involved with the South African Navy base at Simon’s Town as a part-time lecturer in marine and submarine medicine. Dr. Nel obtained a bachelor’s degree (B.Sc.) in clinical pharmacology from the University of Stellenbosch, South Africa, where she also earned a PhD and qualified as a medical doctor. |
| |
|
|
|
Chief of External Relations |
|
| |
| Ms. Norick is responsible for IPM’s strategic engagement with key constituencies and stakeholders worldwide and coordination of IPM’s external outreach across all programs. Ms. Norick has worked on behalf of major U.S. non-governmental organizations involved in developing safe and effective microbicides for nearly a decade. Before entering the microbicide field, she served as senior legislative advisor for many years in the U.S. House of Representatives and Senate, specializing in national security and foreign policy. During her tenure, Ms. Norick routinely managed relevant negotiations on a broad range of issues with foreign government leaders and representatives, United Nations agencies, officials from the U.S. Departments of State and Defense, the U.S. Agency for International Development and others. In a variety of professional capacities, she has traveled extensively in Africa, the Middle East, Europe, Latin America and Asia. Throughout her career, Ms. Norick has been committed to improving the economic, social and health status of women and their families in the developing world. A former Peace Corps volunteer in central Africa, she holds a master’s degree from American University’s School of International Service. |
|
|
|
Executive Director for Resource Development |
|
| |
| Ms. Benjamin is responsible for leading the development and implementation of a comprehensive global development strategy for IPM. Ms. Benjamin comes to IPM from the International Youth Foundation (IYF), where she worked for nearly six years. She served as IYF’s vice president of business development, mobilizing resources from corporations, governments and multilateral organizations for initiatives in 70 countries. She previously served as IYF’s chief financial officer. Ms. Benjamin has private sector experience in financial, management and strategy consulting with Arthur Anderson and with Grant Thornton. In 1999, U.S. President Clinton appointed Ms. Benjamin a White House Fellow, one of the nation’s most prestigious programs for leadership and public service. In this capacity, she worked with the Secretary of Labor on international policies and programs. In 1994, Ms. Benjamin was appointed United Nations humanitarian affairs officer, responsible for coordinating humanitarian aid in Somalia. She also worked with the World Bank History Project, contributing macroeconomic analysis for the Brookings Institution’s 1997 publication entitled The World Bank: Its First Half Century. Ms. Benjamin is a fellow with the U.S.-Japan Foundation and the U.S.-Southern Africa Center for Leadership and Public Values. She is a member of the board of directors of the Echoing Green Foundation and a trustee of North Central College, where she earned her bachelor’s degree in political science and English. Ms. Benjamin holds two graduate degrees from American University in international affairs and applied economics. |
|
|
|
Executive Director for Project Management |
|
| |
| Ms. Douville oversees planning related to IPM’s drug development activities as well as manages the Contracts Group and the newly formed Manufacturing Department, including the CTM Facility in Bethlehem, PA. Prior to joining IPM, Ms. Douville served as vice president of product development at Biosyn, Inc., a corporation developing microbicides against HIV and other STI’s. Ms. Douville spent 14 years at Biosyn where she was responsible for the drug development efforts of compounds in its microbicide pipeline. She oversaw development of the lead candidate microbicide from post-discovery through the initiation of Phase III trials in Africa and the United States, and advanced a second compound from early pre-clinical into a series of international Phase I safety studies. Ms. Douville has extensive experience managing NIH grants and contracts, and NGO grant awards. She has served on the board of the California Microbicide Initiative and on a number of panels and working groups focusing on microbicides. Ms. Douville has a Bachelor of Applied Science from the School of Engineering and Applied Science at the University of Pennsylvania and a BS in Economics from the Wharton School at the University of Pennsylvania. |
|
|
|
Executive Director of External Relations, Europe |
|
| |
| Dr. Mertenskoetter leads IPM’s overall engagement in Europe and directs the work of IPM Belgium. Dr. Mertenskoetter is a former HIV/AIDS physician, and he most recently served as the medical director of Gilead Sciences GmbH, Germany from 2002 to 2007. There he was responsible for developing and implementing Gilead’s clinical research program in HIV and viral hepatitis among other areas. Before that, he was director of medical communications at GlaxoSmithKline. Over the years, Dr. Mertenskoetter has worked in various public-private research programs focusing on the epidemiology of HIV and AIDS, observational research in HIV care, international HIV pharmacovigilance and the introduction of ART for patients in developing countries. Dr. Mertenskoetter received his medical doctorate from the University of Hamburg and his training in tropical medicine and parasitology from the Bernhard Nocht Institute. |
|
|
|
Executive Director for Research and Development |
|
| |
| Dr. Romano is responsible for research and development (R&D) activities at IPM, which include internal drug development projects as well as externally funded microbicide R&D activities. Prior to joining the organization, Dr. Romano served as vice president of research at Biosyn, Inc., a private corporation that develops microbicides against HIV and other STI’s. Dr. Romano’s research at Biosyn focused on HIV-specific and broad spectrum anti-infectives and combination microbicides. Prior to focusing on microbicide research, he spent 10 years in the HIV field at ABL Inc., a subsidiary of AKZO-Nobel. There, he was involved in research related to Kaposi’s sarcoma, cytokine expression and vaccine development. He was also responsible for developing novel diagnostic technologies targeting HIV infection, viral load quantitation and immune response monitoring. He spent three years at the National Cancer Institute of the U.S. National Institutes of Health where his research involved molecular characterization of tumor suppressor genes. Dr. Romano is a molecular biologist and received a BS in biology from Lehigh University, and a MS and PhD in microbiology from Rutgers University. |
|
|
